Biggest News Aggregation in the World
๐Ÿ“ฐ Accessed August News

Page 7 - Accessed August News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Accessed August. Real-time updates on events, politics, business and more.

How Can We Support the Rising Global Population?

There is an urgent need to implement proactive measures so the future population can enjoy a healthy, safe, and sustainable existence. There is a need to establish sustainable processes before the population reaches numbers that exceed what current infrastructure can maintain.
Drcarrrven Shutterstock Sarah Moore Laura Thomson Sarah Mooresep Energy Storage Technologies United Nations Sustainable Development Goals Sdgs

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Producing Renewable Energy with Osmotic Power

Osmotic power is a form of renewable energy that experts have predicted could have the potential to produce half of Europeโ€™s power by 2030. French energy supplier Sweetch is exploring new ways of producing renewable energy via osmotic power to address carbon emissions associated with our reliance on non-renewable fossil fuels.
Sarah Mooresep Sarah Moore Gwladys Fouch Laura Thomson Kertu Shutterstock First Company To Offera Large

Novartis : Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer -September 14, 2023 at 01:26 pm EDT

Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed August 2023. European Society...
San Antonio United States France General Comunidad Autonoma De Cataluna Samir Shah Richard Jarvis

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...
United Kingdom United States Daiichi Sankyo Single Institution Study Lung Ambition Alliance Company On Social Media Astrazeneca

ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial

Daiichi Sankyo and AstraZenecaโ€™s ENHERTU showed objective response rates of 49% and 56% with 5.4 mg/kg and 6.4 mg/kg doses, respectively, in primary analysis ENHERTU provided a median...
United States Daiichi Sankyo Ken Takeshita Susan Galbraith Belfer Center Drug Administration

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science